DEA proposes new telehealth rules for prescribing controlled substances

The Drug Enforcement Agency has proposed new rules for prescribing controlled substances via telemedicine after the COVID-19 Public Health Emergency expires. 

The new rules are intended to bridge the gap between the DEA's current PHE waivers and a post-PHE telehealth environment, according to a Feb. 24 release from the DEA. 

Four things to know:

  1. The new rules would provide safeguards for telemedicine consultations conducted by a medical practitioner that has never met with a patient in-person and controlled substance prescribing via telemedicine. 

  2. The new rules would allow practitioners to prescribe a 30-day supply of Schedule III-V non-narcotic controlled medications via telemedicine. 

  3. The new rules would also allow practitioners to prescribe a 30-day supply of buprenorphine for the treatment of opioid use disorder via telemedicine.
     
  4. These new rules would allow clinicians to prescribe these substances without an in-person evaluation or referral from a medical practitioner, as long as the prescription is consistent with federal and state laws. 

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like